New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Last Close
Oct 15  •  04:00PM ET
10.33
Dollar change
-0.19
Percentage change
-1.81
%
IndexRUT P/E- EPS (ttm)-1.36 Insider Own55.20% Shs Outstand13.47M Perf Week-9.74%
Market Cap140.80M Forward P/E- EPS next Y-1.48 Insider Trans0.12% Shs Float6.11M Perf Month-8.34%
Enterprise Value137.67M PEG- EPS next Q-0.36 Inst Own10.51% Short Float22.45% Perf Quarter-16.02%
Income-17.99M P/S- EPS this Y-7.44% Inst Trans7.31% Short Ratio19.39 Perf Half Y15.42%
Sales0.00M P/B96.69 EPS next Y-13.85% ROA-347.56% Short Interest1.37M Perf YTD-8.01%
Book/sh0.11 P/C44.98 EPS next 5Y-6.70% ROE-491.94% 52W High15.47 -33.23% Perf Year-24.76%
Cash/sh0.23 P/FCF- EPS past 3/5Y-50.90% -32.98% ROIC-1249.93% 52W Low8.06 28.16% Perf 3Y7.72%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility5.73% 5.35% Perf 5Y110.82%
Dividend TTM- EV/Sales- EPS Y/Y TTM-71.59% Oper. Margin- ATR (14)0.59 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.85 Sales Y/Y TTM- Profit Margin- RSI (14)42.04 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.85 EPS Q/Q-49.01% SMA20-4.47% Beta3.03 Target Price45.00
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-8.77% Rel Volume0.54 Prev Close10.52
Employees8 LT Debt/Eq0.00 EarningsAug 11 SMA200-5.74% Avg Volume70.75K Price10.33
IPOSep 25, 2020 Option/ShortNo / Yes EPS/Sales Surpr.-25.00% - Trades Volume38,039 Change-1.81%
Date Action Analyst Rating Change Price Target Change
Aug-20-25Initiated Noble Capital Markets Outperform $45
Sep-01-21Initiated H.C. Wainwright Buy $78
Oct-09-25 06:00AM
Oct-02-25 06:00AM
Sep-30-25 06:00AM
Sep-18-25 06:00AM
Sep-10-25 06:00AM
09:25AM Loading…
Aug-20-25 09:25AM
Aug-19-25 06:00AM
Aug-13-25 06:00AM
Aug-11-25 06:00AM
Apr-03-25 08:00AM
Apr-02-25 06:00AM
Mar-27-25 06:00AM
Mar-17-25 06:45AM
Feb-10-25 06:00AM
Jan-30-25 11:13AM
06:00AM Loading…
Jan-29-25 06:00AM
Jan-27-25 06:00AM
Jan-23-25 06:00AM
Jan-22-25 06:00AM
Jan-14-25 06:15AM
Jan-13-25 07:00AM
Nov-26-24 06:00AM
Nov-18-24 06:00AM
Aug-01-24 06:00AM
Jun-26-24 07:33AM
Jun-17-24 09:00AM
Jun-14-24 06:00AM
May-20-24 09:53PM
Apr-15-24 10:53PM
Apr-10-24 03:30PM
06:00AM Loading…
Mar-13-24 06:00AM
Mar-12-24 06:00AM
Mar-07-24 09:00AM
Feb-27-24 06:00AM
Feb-22-24 06:00AM
Feb-14-24 06:00AM
Nov-21-23 06:00AM
Sep-13-23 05:02PM
Jul-26-23 01:12PM
Jul-18-23 06:53AM
May-10-23 06:32AM
May-09-23 06:40AM
May-08-23 06:41AM
May-05-23 06:58AM
May-04-23 06:29AM
May-03-23 06:46AM
May-02-23 06:46AM
May-01-23 06:45AM
Apr-28-23 07:04AM
Apr-27-23 06:47AM
Apr-26-23 06:26AM
Apr-20-23 07:03AM
Apr-19-23 06:53AM
Apr-17-23 06:54AM
Apr-14-23 06:37AM
Apr-13-23 06:52AM
Apr-12-23 07:07AM
Apr-11-23 06:58AM
Apr-10-23 06:44AM
Apr-07-23 07:44AM
Apr-06-23 10:37AM
07:20AM
Apr-05-23 06:11AM
Apr-04-23 07:08AM
Apr-03-23 06:48AM
Mar-31-23 06:36AM
Mar-30-23 06:36AM
Mar-29-23 06:32AM
Mar-28-23 06:46AM
Mar-24-23 06:42AM
Mar-23-23 07:01AM
Mar-21-23 06:23AM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 06:43AM
Feb-27-23 06:50AM
Feb-24-23 07:17AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
Feb-14-23 06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel SnehalCEO and CFOApr 25 '25Buy9.883,60035,5685,570,602Apr 29 06:14 AM
Patel SnehalCEO and CFOApr 17 '25Buy8.985,40048,4925,567,002Apr 22 06:05 AM
Patel SnehalCEO and CFOApr 07 '25Buy9.103,60032,7605,561,602Apr 08 06:05 AM
Patel SnehalCEO and CFOApr 04 '25Buy8.735,50048,0155,558,002Apr 07 07:50 AM
Patel SnehalCEO and CFOJan 10 '25Buy12.512,50031,2755,552,502Jan 13 06:05 AM
Patel SnehalCEO and CFOJan 07 '25Buy13.751,80024,7505,550,002Jan 08 06:10 AM
Patel SnehalCEO and CFOJan 06 '25Buy13.311,10014,6415,548,202Jan 08 06:10 AM
Patel SnehalCEO and CFOJan 03 '25Buy12.953,40044,0305,547,102Jan 07 06:05 AM
Patel SnehalCEO and CFOJan 02 '25Buy11.972,00023,9405,543,702Jan 06 06:05 AM
Patel SnehalCEO and CFODec 31 '24Buy11.362,40027,2645,541,702Jan 03 06:05 AM
Patel SnehalCEO and CFODec 30 '24Buy11.123,20035,5845,539,302Jan 02 06:05 AM
Thompson JayeVP Clinical Reg AffairsNov 21 '24Buy12.911,00012,910264,148Nov 25 06:03 AM